<DOC>
	<DOCNO>NCT02832362</DOCNO>
	<brief_summary>This single-center , randomize , parallel-group , placebo-controlled study assess local nasal tolerability safety multiple administration topically ( intranasally ) administer 1146A deliver nasal spray applicator healthy adult participant</brief_summary>
	<brief_title>Local Nasal Tolerability Safety Study 1146A Healthy Adult Participants</brief_title>
	<detailed_description />
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Carbopol 940</mesh_term>
	<criteria>Demonstrates understand study procedure , restriction willingness participate evidenced voluntary write informed consent receive sign date copy inform consent form . Willing confine 9 day ( 8 night ) acceptance standardize food beverage throughout confine study period Aged 18 55 year inclusive Male female Good general mental health , opinion investigator medically qualify designee , clinically significant relevant abnormality medical history upon physical nasal examination Participant free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer Females childbearing potential , opinion investigator , practice reliable method contraception . Adequate contraception define abstinence , oral contraceptive , either combined progestogen alone injectable progestogen implant levonorgestrel estrogenic vaginal ring percutaneous contraceptive patch intrauterine device intrauterine system double barrier method ( condom occlusive cap [ diaphragm cervical vault cap ] plus spermicidal agent [ foam , gel , film , cream , suppository ] ) male partner sterilization prior female participant 's entry study , male sole partner participant Women positive urine pregnancy test Women breastfeed History malignancy neoplastic disease organ system ( except localize basal cell skin carcinoma ) , treat untreated , within past 5 year prior screen , regardless whether evidence local recurrence metastasis , clinically relevant chronic acute infectious illness febrile infection within two week prior start study , History ( within 5 year prior study start ) evidence cardiovascular , pulmonary , renal , hepatic , gastrointestinal , hematological , endocrinological , metabolic , autoimmune , neurological , psychiatric disease screen , participant use medication therapy could interfere study evaluation proper washout period medication therapy anticipate require concomitant intranasal medication period time throughout study , condition prohibits participant actuate nasal spray device ( severe rheumatoid arthritis ; deform hand finger ; miss finger ) , Nasal disease ( ) likely affect deposition intranasal medication , acute chronic sinusitis , rhinitis medicamentosa , clinically significant polyposis , clinically significant nasal structural abnormality Known suspected intolerance hypersensitivity study medication , excipients , investigational device material , medication similar chemical class , history drug hypersensitivity , asthma , urticaria , significant allergic diathesis , know suspected contraindication , include history allergy , photosensitivity study medication/s Participation another clinical study ( include cosmetic study ) receipt investigational drug within 30 day screen 5 halflives clinical study investigational drug , whichever longer , Previously enrol current study Current smoker smoke used nicotine containing product within 5 year screen , history ( within 5 year prior study start ) evidence illicit drug abuse investigator suspect current drug use drug class include limited barbiturate , amphetamine , benzodiazepine , cocaine , opiates , cannabis illicit drug ( verified urine drug screen reliable evidence ) , history evidence current alcohol abuse participant report regular average alcohol consumption exceed 18 g ( woman ) 35 g ( men ) pure alcohol per day , i.e . 1 drink/day woman 2 drinks/day men ( 1 drink = 150 mL wine 360 mL beer 45 mL hard liquor ) within 6 month screen Nonacceptance standardize food beverage throughout confine study period , Ingestion food contain poppy seed ( muffin , bagel , cake , etc ) within 24 hour admission study site Persons directly indirectly involved execution protocol , include employee contract research organization ( CRO ) person relate , employee sponsor study site member immediate family On nasal examination , presence superficial moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation ( Grade 1B 4 ) screen visit Day 1 , Participants difficulty use nasal spray applicator , `` Vulnerable '' individual ( defined Institutional Review Board ( IRB ) e.g . incarcerated person ) , condition identify protocol opinion investigator would confound evaluation interpretation study data may put participant risk , consumption alcoholcontaining product within 24 hour confinement throughout confine study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>